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Understanding the relationship between the pathophysiology of infectious disease, the biology of the 
causative agent and the development of therapeutic and diagnostic approaches is dependent on the 
synthesis of a wide range of types of information. Provision of a comprehensive and integrated disease 
phenotype knowledgebase has the potential to provide novel and orthogonal sources of information for 
the understanding of infectious agent pathogenesis, and support for research on disease mechanisms. 
We have developed PathoPhenoDB, a database containing pathogen-to-phenotype associations. 
PathoPhenoDB relies on manual curation of pathogen-disease relations, on ontology-based text 
mining as well as manual curation to associate host disease phenotypes with infectious agents. Using 
Semantic Web technologies, PathoPhenoDB also links to knowledge about drug resistance mechanisms 
and drugs used in the treatment of infectious diseases. PathoPhenoDB is accessible at http://patho.
phenomebrowser.net/, and the data are freely available through a public SPaRQL endpoint.
Background & Summary
The 2016 Global burden of disease study estimated that infectious diseases as part of the communicable, mater-
nal, nutritional and neonatal complex (CMNN) accounted for 19% of global mortality in 2016, and constitute the 
second most important cause of deaths globally1. They remain the top cause of mortality in most of the develop-
ing countries, mainly in Africa, at 56% in 2015. The annual infectious disease mortality in the world is reported 
as 10,598 (per 100,000 people) by the World Health Organization (WHO). Lower respiratory tract infections 
are the most likely cause of mortality due to infectious disease, followed by diarrhoeal diseases, tuberculosis and 
HIV/AIDS which were responsible for 3.2 million, 1.4 million, 1.4 million and 1.1 million deaths respectively in 
2015 alone (http://who.int/en/). Infectious diseases have highly significant economic impact through morbidity 
and mortality, especially for the developing countries2. They affect multiple components of human development 
including income, health, education and productivity through lost life years, and cause devastating consequences 
worldwide.
Infectious diseases are caused by a wide range of organisms (viruses, bacteria, fungi, worms, protozoa) that are 
generally considered as pathogens. Antimicrobial, antihelminthic, antiprotozoal and antifungal drugs are often 
the first line therapy for infectious diseases. However, drug resistance accumulates over time due to selection of 
genetic changes in pathogen populations when they are exposed to therapeutic agents. It now becomes crucial 
to develop strategies that can identify a pathogen rapidly and determine successful treatment options based on 
functional information in the pathogen relevant to drug resistance mechanisms.
While functional information about pathogens and their interactions with hosts is increasingly becoming 
available on a molecular level through large-scale studies3, disease phenotypes observed in an infected patient 
are not only mediated through direct molecular interactions between pathogen and host but also through the 
1computer, electrical and Mathematical Sciences & engineering with Division, computational Bioscience Research 
Center, King Abdullah University of Science and Technology, Thuwal, 23955, Saudi Arabia. 2Department of 
Physiology, Development & Neuroscience, University of Cambridge, Downing Street, Cambridge, CB2 3EG, United 
Kingdom. correspondence and requests for materials should be addressed to R.H. (email: robert.hoehndorf@kaust.
edu.sa)
Received: 10 December 2018
Accepted: 7 May 2019
Published: xx xx xxxx
Data DeScRiPtoR
oPeN
2Scientific Data |            (2019) 6:79  | https://doi.org/10.1038/s41597-019-0090-x
www.nature.com/scientificdatawww.nature.com/scientificdata/
immune response and physiological and patho-physiological processes affecting the entire host organism. 
Phenotypes observed in a patient provide a readout for all these processes and generally provide a proxy for the 
mechanism through which pathogens elicit their signs and symptoms4. While there is a wide range of phenotypes 
that are shared across multiple infectious diseases as a result of common immune system processes and immune 
response to pathogens, certain host-pathogen interactions may result in specific phenotypes through which path-
ogens can be broadly distinguished.
Phenotype-based computational analysis methods can uncover molecular mechanisms in Mendelian diseases5, 
and have been applied to the discovery of disease mechanisms from animal models6 and to the investigation 
of drug mechanisms and drug repurposing7. In the area of infectious disease, similar methods may be applica-
ble, mainly to investigate mechanisms of virulence and pathogenicity. Application of phenotype-based methods 
requires matching phenotypes observed in a particular physiological or pathological state with the phenotypes 
known to be associated with pathogens6,8, and use of this information to reveal molecular mechanisms. Currently, 
there is no comprehensive database of pathogen-to-phenotype associations that can be used for this purpose.
We have developed PathoPhenoDB, a database of pathogen-to-phenotype associations intended to support 
infectious disease research. PathoPhenoDB is a database which relies on pathogen–disease associations curated 
manually from public resources and the scientific literature. We further expanded the pathogen–disease asso-
ciations by complementary text-mined data9. PathoPhenoDB links pathogens to disease phenotypes based on 
manually-curated and text-mined disease–phenotype associations. Furthermore, PathoPhenoDB links pathogens 
to drugs10 that are known to treat infections by the pathogen, and further links pathogens to drug resistance genes 
and proteins11 as well as to the drugs against which these genes or proteins convey resistance so that the information 
in PathoPhenoDB can be utilized directly for research on drug resistance mechanisms. PathoPhenoDB is freely 
available on http://patho.phenomebrowser.net, and the data can be obtained through a public SPARQL endpoint.
Methods
Data collection and integration. We developed PathoPhenoDB by considering the FAIR data principles12. 
Our expert gathered manually at least one possible human pathogen for every of infectious disease class listed 
in the Human Disease Ontology (DO)13 from public resources. Therefore, we cover all of the infectious diseases 
from DO and intend to maintain this coverage with future extensions of DO. We gathered the pathogen–disease 
associations mainly from the Centers for Disease Control and Prevention (CDC) (https://www.cdc.gov/, 87%) as 
well as from Wikipedia (mainly from the list of infectious disease, https://en.wikipedia.org/wiki/List_of_infec-
tious_diseases), the Disease Ontology, and literature in PubMed; we used the labels of the infectious disease for 
which we wanted to identify a causative pathogen as search terms.
We used lexical matching to map the gathered diseases to DO and pathogens to NCBI Taxonomy 
semi-automatically. In the cases where we could not find an exact match of a pathogen in the NCBI taxonomy, we 
mapped the pathogen to their parent class. For example, instead of assigning Spirillium minus to Sodoku disease, 
we assigned the higher taxon Spirillium to Sodoku disease due to Spirillium minus not being listed in the NCBI 
taxonomy.
Furthermore, we extracted pathogen–disease associations from all the Open Access full-text PMC articles 
(version:v.2017.12, size: 1.8 million) from Europe PMC14 by using an ontology-based text mining approach9, and 
we included the resulting association in PathoPhenoDB. Briefly, our system extracts pathogen–disease associa-
tion from text in three steps. First, it annotates pathogen and disease names in text by using dictionaries compiled 
from NCBI Taxonomy and DO and propagates the annotations by using the hierarchical class structure defined 
in the ontologies. Second, it identifies pathogen–disease pairs based on their co-occurrences at the sentence level. 
Third, it applies a statistical analysis to filter the pairs based on their co-occurrence statistics and the Normalized 
Pointwise Mutual Information (NPMI)15 measure. We evaluated the performance of our system manually on 50 
randomly selected pathogen–disease associations. Our system achieved a precision of 64%, a recall of 84% and 
an F-score of 73%9.
Here, we consider infectious disease phenotypes as those observable or measurable characteristics of a host 
which constitute the signs and symptoms of the pathogen-induced disease. We restrict the range of phenotypic 
characteristics we consider to the phenotypes that are represented by classes in the Human Phenotype Ontology 
(HPO)16 or the Mammalian Phenotype (MP) ontology17.
Disease phenotypes were extracted semi-automatically from class definitions in the Disease Ontology and 
automatically from PubMed abstracts by using ontology-based text mining18. Briefly, during our manual extrac-
tion process, we mapped the phenotypes to HPO and MP automatically where there is an exact match oth-
erwise we mapped them manually. Overall, we were able to map 90% (293/324) of the phenotypes linked to 
the infectious diseases in DO to HPO and MP. For text mining the disease–phenotype associations, we first 
identified co-occurrences between disease names from DO and phenotype names from the Human Phenotype 
Ontology (HPO) (downloaded on 14 May 2018) and the Mammalian Phenotype Ontology (MP) (downloaded 
on 14 May 2018) in all PubMed abstracts (approximately 28 million). To integrate the HPO and MP ontologies we 
use the PhenomeNET ontology6. Secondly, we identified the disease–phenotype co-occurrences and calculated 
the strength of each co-occurrence based on an ontology-based normalized point-wise mutual information18,19. 
Thirdly, we selected a threshold for the most “useful” co-occurrences by evaluating the performance of our sys-
tem in candidate disease gene prediction at different NPMI ranks. Our evaluation results show that the system 
achieves its best performance at the NPMI rank 12.
We extracted drug information from the SIDER database10 by resolving the cross-references between UMLS 
concept identifiers and DO identifiers. We gathered information about drug resistance from the Antibiotic 
Resistance Ontology (ARO)11. For this purpose, we matched the ARO accession and iterated through the ontol-
ogy hierarchy using the subclass and confers-resistance-to relationships in ARO to retrieve the drugs. Using the 
Entrez API, we then identified the DNA accession that conveys drug resistance in the NCBI nucleotide database 
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to retrieve the organism and its NCBI Taxonomy identifier. While, diseases are linked to pathogens, drugs, and 
phenotypes, the pathogens are linked to their drug resistance proteins, DNA accession and drugs to which they 
are resistant.
Semantic similarity computation. We calculate the semantic similarities using Resnik’s semantic similar-
ity measure20. We represent each pathogen p with a set containing all the possible phenotypes it can cause in its 
host (based on the data in PathoPhenoDB). We formulate a query by a set of phenotypes and rank pathogens 
based on their similarity scores to the query. Resnik’s semantic similarity measurement is based on information 
content of a class c which we define as the negative log of the probability of a pathogen being associated with a 
phenotype class c: ic(c) = −log p(c). Resnik’s similarity between two phenotype classes c1 and c2 is then defined as 
= ∈sim c c ic c( , ) max ( )c S c c1 2 ( , )1 2  where  =S c c c c c c c( , ) { and }1 2 1 2 , i.e., S(c1, c2) is the set of shared superclasses of c1 and c2. As pathogens are associated with multiple phenotypes and a phenotype-based query will also consist 
of multiple phenotypes, we use the Best-Match Average strategy to calculate the similarity between a pathogen p 
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Additionally, we use the OPA2Vec framework21 to generate “ontology embeddings” for the pathogens, and 
we use a t-SNE dimensionality reduction22 to visualize the resulting embeddings and their relations. An ontol-
ogy embedding is a function that maps classes, relations, and instances in an ontology to vectors within an 
n-dimensional vector space21.
implementation. We developed the web application for our database using Python Django framework 
(https://djangoproject.com/) for the backend and ReactJS (https://reactjs.org/) for the frontend services. We store 
only identifiers for the links in our database and retrieve all the annotations and additional data such as names 
from the AberOWL23 ontology repository using its REST API. For this purpose, we created compressed versions 
of DO, PhenomeNET and NCBITAXON24 ontologies.
Data Records
PathoPhenoDB is available at http://patho.phenomebrowser.net and its content is accessible through a public 
SPARQL endpoint. Every release of the data is deposited in the Zenodo data repository25.
PathoPhenoDB is a database of human pathogens, the diseases and phenotypes they elicit in human organ-
isms, and information related to drug treatments and mechanisms of drug resistance. Specifically, PathoPhenoDB 
contains associations between pathogens and diseases, between pathogens and phenotypes, between drugs that 
are approved to treat particular pathogens, and it identifies genes or proteins within pathogens that can convey 
resistance to particular drugs. Figure 1 provides a high-level overview of the information in PathoPhenoDB. 
PathoPhenoDB is constructed through a combination of manual curation of scientific literature, text mining, 
information extraction, and data integration approaches using Semantic Web technologies.
In PathoPhenoDB, we consider a pathogen to be any kind of bacterium, virus, fungus, protozoan, parasite, or 
other type of organism that is known to be able to cause a disease or abnormal phenotype in humans. With this 
broad view of pathogens, PathoPhenoDB includes 32 types of parasitic insects, 115 fungi, 208 bacteria, 47 proto-
zoa, 175 viruses, and 115 taxa of parasitic worms. Our database currently covers a total of 1,170 pathogen–disease 
associations between 508 infectious diseases and 692 taxa of pathogens. For a total of 130 infectious diseases and 
399 pathogen–disease associations, we also include information about drugs that can treat the disease and patho-
gen. We further include information on known mechanisms of drug resistance for 30 pathogens representing 78 
pathogen–disease associations. While PathoPhenoDB is largely based on manually curated information, we also 
extracted pathogen–disease associations from the biomedical literature9 and use this information to enrich the 
content of our database. Statistics relevant to the text-mined content is available from the web site http://patho.
phenomebrowser.net.
Fig. 1 Schematic overview of the types of entities and their relations in PathoPhenoDB.
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We use the Human Disease Ontology (DO)13 as a reference for infectious diseases in humans and base all our 
disease-related information on the DO. To associate pathogens with phenotypes, we follow a data integration 
approach and deductive inference where we utilize pathogen–disease associations to propagate phenotypes asso-
ciated with infectious disease in DO18 to the pathogens that cause the diseases. We performed the inferences using 
the reasoner Elk, querying for subclass associations. The inferences of new subclass relations will be based on 
other axioms in the ontology. In PathoPhenoDB, we utilize 1,140 of 1,143 pathogen–disease associations to assign 
phenotypes for 476 (out of 508) infectious diseases to pathogens. For example, we use the phenotypes assigned to 
the DO class Plasmodium malariae malaria (DOID:14324), which includes phenotypes such as “episodic fever”, 
“hemolysis” and “anura”, and assign all phenotypes of this disease to Plasmodium malariae (NCBITaxon:5858) 
based on the association between Plasmodium malariae and Plasmodium malariae malaria.
As vocabulary for phenotypes we use a combination of the Human Phenotype Ontology (HPO)16 and the 
Mammalian Phenotype Ontology (MP)26. While both ontologies are formally distinct and use different iden-
tifiers, they can be integrated and aligned through cross-species phenotype ontologies such as PhenomeNET6 
or UberPheno27. For our database, we use the PhenomeNET ontology as it has been applied in a variety of 
phenotype-driven studies of molecular mechanisms28,29. The 692 pathogens in PathoPhenoDB are associated 
with 1,719 distinct phenotypes from HPO and 479 distinct phenotypes from MP. On average, each pathogen is 
directly associated with 20 phenotypes.
Using ontologies to represent phenotypes enables deductive inferences using the ontology axioms30,31. To 
exploit these inferences, we represent the data in PathoPhenoDB using the RDF format (described in the meth-
ods section) and it is available for querying by using SPARQL endpoint from the web site. We use the Relation 
Ontology (RO)32 and the Semanticscience Integrated Ontology (SIO)33 to represent the relations between the 
entities. For the relations in Fig. 1, the has_phenotype relation corresponds to RO:0002200, has_path-
ogen to RO:0002556 and the is_treated_by relation to RO:0002302.
As we gathered pathogen–disease and disease–phenotype associations using two different methods – text 
mining and manual curation – we use the has_annotation relation from SIO (SIO:000255) to reify 
annotation assertions; in particular, we generate annotation objects that consists of a relation, an annotation 
value of the relation, and an evidence code that represents the level of evidence for the annotation. For exam-
ple, to represent the information that Actinomadura madurae (NCBITaxon:1993) may cause Actinomycosis 
(DOID:8478), as obtained from text mining, we generate a new annotation object consisting of the pathogen 
of (RO:0002556) relation to Actinomycosis (DOID:8478) and the has evidence (RO:0002558) relation to 
manual assertion (ECO:0000203) in the Evidence and Conclusion Ontology (ECO)34.
In addition to reusing relations from established ontologies, we generate new relations (resistant to, 
resistance-conferring protein, resistance-conferring genomic feature) to capture information on drug resistance. 
We consider resistant to as a primitive relation between individuals: x is resistant to y if and only if x is a pathogen 
and y is a chemical compound, and x does not decrease its fitness when exposed to y. The class of pathogens X is 
resistant to the class of chemicals Y if and only if all instances of X are resistant to some instance of Y. Our intu-
ition is that in order for X to be resistant to Y, X needs to contain a resistance-conferring feature, either encoded 
on DNA, RNA, or a protein. Being a resistance-conferring feature is a ternary relation that relates a class of path-
ogens, chemicals, and the resistance-conferring feature: x is a resistance-conferring feature for y with respect to z if 
and only if (a) x is a part of y, (b) y is resistant to z, (c) x is normally not a part of y and y is normally not resistant 
to z, and (d) y would not be resistant to z if x would not be a part of y. “Normally” here is a comparison to a ref-
erence or “normal” representation of the pathogen organism and which can be formalized, for example, through 
non-monotonic reasoning35.
We plan to update PathoPhenoDB regularly each year by running the text mining workflows. The data in 
PathoPhenoDB is also updated irregularly when new data becomes available or issues with existing data are 
resolved. To report issues such as incorrect or missing associations, we maintain an issue tracker. Data are released 
in RDF format and every release of the data is deposited in the Zenodo data repository25.
technical Validation
Figure 2 presents the search in PathoPhenoDB for a particular phenotype, Brain atrophy. The query retrieves 
all the infectious diseases associated with brain atrophy and their causative pathogens. Due to the use of infer-
ence and Semantic Web technologies, PathoPhenoDB can identify both direct and indirect associations between 
pathogens and phenotypes. We classify an association as direct if it is explicitly asserted during the curation. We 
classify an association as indirect if it is inferred based on a direct association and application of inference over 
the subclass hierarchy of the ontologies. For example, PathoPhenoDB does not cover any infectious disease that 
is directly associated with Toxocara (NCBITaxon:6264). However, a query for Toxocara will return all the 
disease and phenotype associations linked to its subclasses, including Toxocara canis (NCBITaxon:6265) and 
Toxocara canti (NCBITaxon:6266) as indirect associations. Using this kind of inference, PathoPhenoDB can 
provide useful and relevant knowledge on the entities of interest while using the background knowledge con-
tained in the class hierarchy of the ontologies.
In addition to querying our database using Semantic Web technologies, the information in PathoPhenoDB can 
also be used to perform approximate queries using semantic similarity measures20. We test the similarity-based 
retrieval of pathogens by generating synthetic sets of phenotypes that consist of randomly chosen subsets of phe-
notypes associated with an infectious disease, and trying to identify the pathogen causing the disease based on 
semantic similarity over phenotype ontologies. Figure 3 shows the performance of recovering pathogens through 
semantic similarity when providing a varying number of symptoms. The model achieves a ROCAUC of over 
86% using a single phenotype as query and does not significantly improve with more phenotypes added. We 
speculate that this is the result of pathogens falling in distinct phenotypic groups and that semantic similarity 
does not appropriately weight the distinguishing phenotypes within the group (because they are too general). We 
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Fig. 2 Search in PathoPhenoDB.
Fig. 3 Pathogen recovery with different number of symptoms.
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further use a data-driven semantic similarity measure based on ontology embeddings21 to visualize the pathogens 
and their disease phenotypes in a 2-dimensional space using a t-SNE dimensionality reduction22; phenotypically 
related pathogens are closer together in this space and the visualization of the embeddings can be used to identify 
pathogens that elicit similar phenotypes in their hosts. Figure 4 shows the resulting plot. We also make this figure 
available on our website to enable interactive exploration of pathogens based on their phenotype similarity.
Furthermore, the data in PathoPhenoDB has also been used to predict host-pathogen interactions36. The 
assumption in this application is that host phenotypes are the result of molecular interactions between the 
pathogen and a host protein. Comparing the phenotypes associated with pathogens in PathoPhenoDB and 
loss-of-function phenotypes could successfully predict these interactions36.
Usage Notes
PathoPhenoDB covers information about known mechanisms of drug resistance (i.e., of genes and proteins that 
have the potential or disposition to convey resistance to certain drugs) gathered from the ARO11. This informa-
tion can be used to determine (a) potential drugs to treat an infection caused by a particular pathogen, and (b) 
determine known mechanisms of resistance to such a treatment. It can be useful mainly in computational studies 
relying on data integration, but can also provide a link to the relevant resources that contain information about 
molecular markers of drug resistance.
One limitation of our dataset is that we do not handle variability of symptoms, mainly because we lack the 
necessary information to determine the frequency of symptoms in infections. For the most part, this information 
is not reported in the literature except as individual case studies. Instead, PathoPhenoDB contains a set of canon-
ical symptoms and should be used in conjunction with a measure of relevance of a particular symptom such as 
through information content measures in semantic similarity computation.
Another limitation of our dataset is the inclusion of text mining results for some relations, specifically for 
pathogen–disease and disease–phenotype associations. We evaluate and report the performance of our text min-
ing systems on these tasks, and while the majority of text mined relations will be accurate, there is nevertheless a 
probability that some information in PathoPhenoDB is incorrect. One source of low precision in our text mining 
evaluation is the use of ontologies and our ability to predict relations between more specific or more general types 
of entities, which we consider as false positive predictions. Furthermore, our text mining method has limitations 
due to its lexical components. When we or users of PathoPhenoDB identify incorrect or missing associations, 
we manually remove or add relations, and these manual additions can be identified from their evidence codes.
Infectious disease research and diagnosis of infectious disease is rapidly changing with the application of 
sequencing technologies. Current routine clinical pathogen identification methods often do not identify the 
most effective and specific treatment options37, or are not able to identify the causative pathogens rapidly. Recent 
achievements in next generation sequencing technologies (NGS) have led clinical microbiology to move in the 
direction of molecular diagnostic approaches38. NGS, in particular metagenomics and metatranscriptomics, can 
address the limitations of traditional microbial diagnostic methods by offering unbiased identification of organ-
isms and can also be used to identify drug resistance and other functional information. Furthermore, metagen-
omics enables us to detect non-culturable organisms and multiple infections, and already shows great potential to 
be used in the rapid and accurate identification of pathogens39,40.
While NGS-based approaches have the potential to identify a wide range of pathogens in a single sequencing 
run, they may identify multiple different microorganisms that have the potential to cause infections. Identification 
of the causative pathogen among the set of pathogens identified through metagenomics approaches, is an addi-
tional challenge. In the future, matching the phenotypes observed in a patient to phenotype in PathoPhenoDB 
Fig. 4 t-SNE plot of pathogens. Pathogens are represented using their ontology embeddings that have been 
generated using their associated phenotypes. Viruses are colored in blue, bacteria in orange, all other pathogens 
in green.
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may provide additional features that can be combined with information from NGS to improve diagnosis and 
treatment of infectious disease.
As a more direct application of PathoPhenoDB, we envision its use in investigating molecular mechanisms 
underlying infectious diseases, specifically host-pathogen interactions. Phenotypes indirectly encode the molecu-
lar interactions between hosts and pathogens and therefore may be used to study the molecular basis of infectious 
disease36.
code availability
The source code for PathoPhenoDB is freely available at https://github.com/bio-ontology-research-group/
pathophenodb.
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